Why the study?
Mouse OSM and LIF selectively activate their cognate receptors whereas human OSM activates both OSMR and LIFR, preventing efficient translation of mouse post-MI data into clinical applications.
Does an engineered human-like OSM (hlOSM) protein improve functional and structural integrity in mice after myocardial infarction?
Does an engineered human-like OSM (hlOSM) protein improve functional and structural integrity in mice after myocardial infarction?
Simultaneous activation of OSMR and LIFR using a human-like OSM variant provides cardioprotection and preserves heart function after myocardial infarction in mice.
hlOSM enables human-relevant post-MI signaling studies; leaves open clinical translation and efficacy.
Oncostatin M (OSM) and leukemia inhibitory factor (LIF) signaling protects the heart after myocardial infarction (MI). In mice, oncostatin M receptor (OSMR) and leukemia inhibitory factor receptor (LIFR) are selectively activated by the respective cognate ligands while OSM activates both the OSMR and LIFR in humans, which prevents efficient translation of mouse data into potential clinical applications. We used an engineered human-like OSM (hlOSM) protein, capable to signal via both OSMR and LIFR, to evaluate beneficial effects on cardiomyocytes and hearts after MI in comparison to selective stimulation of either LIFR or OSMR. Cell viability assays, transcriptome and immunoblot analysis revealed increased survival of hypoxic cardiomyocytes by mLIF, mOSM and hlOSM stimulation, associated with increased activation of STAT3. Kinetic expression profiling of infarcted hearts further specified a transient increase of OSM and LIF during the early inflammatory phase of cardiac remodeling. A post-infarction delivery of hlOSM but not mOSM or mLIF within this time period combined with cardiac magnetic resonance imaging-based strain analysis uncovered a global cardioprotective effect on infarcted hearts. Our data conclusively suggest that a simultaneous and rapid activation of OSMR and LIFR after MI offers a therapeutic opportunity to preserve functional and structural integrity of the infarcted heart.
No takes yet. Share an insight, caveat, or question.
Lörchner et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: